315 related articles for article (PubMed ID: 10364332)
21. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone.
Borkow G; Fletcher RS; Barnard J; Arion D; Motakis D; Dmitrienko GI; Parniak MA
Biochemistry; 1997 Mar; 36(11):3179-85. PubMed ID: 9115994
[TBL] [Abstract][Full Text] [Related]
22. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
[TBL] [Abstract][Full Text] [Related]
23. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
[TBL] [Abstract][Full Text] [Related]
24. Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.
Wang J; Li D; Bambara RA; Dykes C
J Gen Virol; 2013 Oct; 94(Pt 10):2297-2308. PubMed ID: 23804564
[TBL] [Abstract][Full Text] [Related]
25. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
26. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
27. Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.
Eshleman SH; Jones D; Galovich J; Paxinos EE; Petropoulos CJ; Jackson JB; Parkin N
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):289-93. PubMed ID: 16545016
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.
Gao Y; Paxinos E; Galovich J; Troyer R; Baird H; Abreha M; Kityo C; Mugyenyi P; Petropoulos C; Arts EJ
J Virol; 2004 May; 78(10):5390-401. PubMed ID: 15113918
[TBL] [Abstract][Full Text] [Related]
29. A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
Harrigan PR; Salim M; Stammers DK; Wynhoven B; Brumme ZL; McKenna P; Larder B; Kemp SD
J Virol; 2002 Jul; 76(13):6836-40. PubMed ID: 12050397
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
[TBL] [Abstract][Full Text] [Related]
31. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Wainberg MA
Antimicrob Agents Chemother; 2002 Jul; 46(7):2087-94. PubMed ID: 12069959
[TBL] [Abstract][Full Text] [Related]
32. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
33. Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication.
Fisher TS; Joshi P; Prasad VR
J Virol; 2002 Apr; 76(8):4068-72. PubMed ID: 11907245
[TBL] [Abstract][Full Text] [Related]
34. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.
Koval CE; Dykes C; Wang J; Demeter LM
Virology; 2006 Sep; 353(1):184-92. PubMed ID: 16797050
[TBL] [Abstract][Full Text] [Related]
35. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.
Ferris RG; Hazen RJ; Roberts GB; St Clair MH; Chan JH; Romines KR; Freeman GA; Tidwell JH; Schaller LT; Cowan JR; Short SA; Weaver KL; Selleseth DW; Moniri KR; Boone LR
Antimicrob Agents Chemother; 2005 Oct; 49(10):4046-51. PubMed ID: 16189079
[TBL] [Abstract][Full Text] [Related]
36. The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
Ambrose Z; Herman BD; Sheen CW; Zelina S; Moore KL; Tachedjian G; Nissley DV; Sluis-Cremer N
J Virol; 2009 Apr; 83(8):3826-33. PubMed ID: 19193782
[TBL] [Abstract][Full Text] [Related]
37. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
[TBL] [Abstract][Full Text] [Related]
38. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.
Uhlmann EJ; Tebas P; Storch GA; Powderly WG; Lie YS; Whitcomb JM; Hellmann NS; Arens MQ
J Clin Virol; 2004 Nov; 31(3):198-203. PubMed ID: 15465412
[TBL] [Abstract][Full Text] [Related]
39. Drug targeting of HIV-1 RNA.DNA hybrid structures: thermodynamics of recognition and impact on reverse transcriptase-mediated ribonuclease H activity and viral replication.
Li TK; Barbieri CM; Lin HC; Rabson AB; Yang G; Fan Y; Gaffney BL; Jones RA; Pilch DS
Biochemistry; 2004 Aug; 43(30):9732-42. PubMed ID: 15274628
[TBL] [Abstract][Full Text] [Related]
40. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Naeger LK; Margot NA; Miller MD
Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
